872 related articles for article (PubMed ID: 25963969)
1. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
Singh JA; Akhras KS; Shiozawa A
Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
[TBL] [Abstract][Full Text] [Related]
2. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
3. A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database.
Altan A; Shiozawa A; Bancroft T; Singh JA
J Clin Rheumatol; 2015 Dec; 21(8):411-8. PubMed ID: 26580304
[TBL] [Abstract][Full Text] [Related]
4. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
5. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
6. Serum urate levels and gout flares: analysis from managed care data.
Sarawate CA; Patel PA; Schumacher HR; Yang W; Brewer KK; Bakst AW
J Clin Rheumatol; 2006 Apr; 12(2):61-5. PubMed ID: 16601538
[TBL] [Abstract][Full Text] [Related]
7. Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Chohan S; Becker MA; MacDonald PA; Chefo S; Jackson RL
Arthritis Care Res (Hoboken); 2012 Feb; 64(2):256-61. PubMed ID: 22052584
[TBL] [Abstract][Full Text] [Related]
8. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
Lertnawapan R; Jatuworapruk K
Clin Rheumatol; 2021 Jan; 40(1):255-262. PubMed ID: 32607660
[TBL] [Abstract][Full Text] [Related]
11. Achievement of the target serum urate level among patients with gout treated with allopurinol or febuxostat in an arthritis clinic in the Philippines.
Quilisadio JEC; Salido EO; Penserga EG
Mod Rheumatol; 2021 May; 31(3):755-761. PubMed ID: 32701037
[TBL] [Abstract][Full Text] [Related]
12. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
Smolen LJ; Gahn JC; Mitri G; Shiozawa A
Clin Ther; 2016 Jul; 38(7):1710-25. PubMed ID: 27269247
[TBL] [Abstract][Full Text] [Related]
13. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis.
Borghi C; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):983-92. PubMed ID: 27010159
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.
Gandhi PK; Gentry WM; Ma Q; Bottorff MB
J Manag Care Spec Pharm; 2015 Feb; 21(2):165-75. PubMed ID: 25615006
[TBL] [Abstract][Full Text] [Related]
15. As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.
Tausche AK; Christoph M; Forkmann M; Richter U; Kopprasch S; Bielitz C; Aringer M; Wunderlich C
Rheumatol Int; 2014 Jan; 34(1):101-9. PubMed ID: 24026528
[TBL] [Abstract][Full Text] [Related]
16. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
17. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
Whelton A; MacDonald PA; Chefo S; Gunawardhana L
Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
[TBL] [Abstract][Full Text] [Related]
18. Febuxostat in the management of gout: a cost-effectiveness analysis.
Smolen LJ; Gahn JC; Mitri G; Shiozawa A
J Med Econ; 2016; 19(3):265-76. PubMed ID: 26535593
[TBL] [Abstract][Full Text] [Related]
19. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.
Khanna P; Khanna D; Storgard C; Baumgartner S; Morlock R
Postgrad Med; 2016 Jan; 128(1):34-40. PubMed ID: 26578028
[TBL] [Abstract][Full Text] [Related]
20. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Becker MA; Schumacher HR; Espinoza LR; Wells AF; MacDonald P; Lloyd E; Lademacher C
Arthritis Res Ther; 2010; 12(2):R63. PubMed ID: 20370912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
